{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:01Z","timestamp":1792089421361,"version":"4.4.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med. Technol."],"abstract":"<jats:p>Nucleoside analogs are very effective antiviral agents with currently over 25 compounds approved for the therapy of viral infections. Still, their successful use against RNA viruses is very recent, despite RNA viruses comprising some of the most damaging human pathogens (e.g., Coronaviruses, Influenza viruses, or <jats:italic>Flaviviridae<\/jats:italic> such as dengue, Zika and hepatitis C viruses). The breakthrough came in 2013\u20132014, when the nucleoside analog Sofosbuvir became one of the cornerstones of current curative treatments for hepatitis C virus (HCV). An analog designed on the same principles, Remdesivir, has been the first approved compound against SARS-CoV-2, the coronavirus that causes the current COVID-19 pandemic. Both of these nucleoside analogs target the RNA-dependent RNA polymerase (RdRp) (NS5B for HCV, nsp12 for SARS-CoV-2). RdRps of RNA viruses display a peculiar elaboration of the classical polymerase architecture that leads to their active site being caged. Thus, triphosphate nucleosides and their analogs must access this active site in several steps along a narrow and dynamic tunnel. This makes straightforward computational approaches such as docking unsuitable for getting atomic-level details of this process. Here we give an account of ribose-modified nucleoside analogs as inhibitors of viral RdRps and of why taking into account the dynamics of these polymerases is necessary to understand nucleotide selection by RdRps. As a case study we use a computational protocol we recently described to examine the approach of the NTP tunnel of HCV NS5B by cellular metabolites of Sofosbuvir. We find major differences with natural nucleotides even at this early stage of nucleotide entry.<\/jats:p>","DOI":"10.3389\/fmedt.2021.705875","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T08:47:31Z","timestamp":1639471651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Recapitulating Trafficking of Nucleosides Into the Active Site of Polymerases of RNA Viruses: The Challenge and the Prize"],"prefix":"10.3389","volume":"3","author":[{"given":"Yves","family":"Boulard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bressanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jcv.2004.02.009","article-title":"Antiviral drugs in current clinical use","volume":"30","author":"De Clercq","year":"2004","journal-title":"J Clin Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2040206618761299","DOI":"10.1177\/2040206618761299","article-title":"Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses","volume":"26","author":"Eyer","year":"2018","journal-title":"Antivir Chem Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2040206618764483","DOI":"10.1177\/2040206618764483","article-title":"Nucleosides for the treatment of respiratory RNA virus infections","volume":"26","author":"Jordan","year":"2018","journal-title":"Antivir Chem Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/510043a","article-title":"Hepatitis C: treatment triumphs","volume":"510","author":"Rice","year":"2014","journal-title":"Nature."},{"key":"B5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0166-3542(03)00007-X","article-title":"Canonical 3'-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase","volume":"58","author":"Shim","year":"2003","journal-title":"Antiviral Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science."},{"key":"B7","doi-asserted-by":"publisher","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro","volume":"278","author":"Migliaccio","year":"2003","journal-title":"J Biol Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1128\/AAC.02666-14","article-title":"Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase","volume":"58","author":"Fung","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cell.2016.08.044","article-title":"Enter Sofosbuvir: the path to curing HCV","volume":"167","author":"Sofia","year":"2016","journal-title":"Cell."},{"key":"B10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S0140-6736(20)32021-3","article-title":"Remdesivir and COVID-19","volume":"396","author":"Glaus","year":"2020","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/protein\/3.6.461","article-title":"An attempt to unify the structure of polymerases","volume":"3","author":"Delarue","year":"1990","journal-title":"Protein Eng."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","article-title":"Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"96","author":"Bressanelli","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/13305","article-title":"Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site","volume":"6","author":"Lesburg","year":"1999","journal-title":"Nat Struct Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1126\/science.aaa5980","article-title":"Kickstarting a viral RNA polymerase","volume":"347","author":"Bressanelli","year":"2015","journal-title":"Science."},{"key":"B19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0092-8674(02)01110-8","article-title":"RNA synthesis in a cage\u2013structural studies of reovirus polymerase lambda3","volume":"111","author":"Tao","year":"2002","journal-title":"Cell."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","article-title":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors","volume":"10","author":"Kirchdoerfer","year":"2019","journal-title":"Nat Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature14008","article-title":"Structure of influenza A polymerase bound to the viral RNA promoter","volume":"516","author":"Pflug","year":"2014","journal-title":"Nature."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/nar\/gkg277","article-title":"A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases","volume":"31","author":"Bruenn","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1128\/JVI.76.7.3482-3492.2002","article-title":"Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides","volume":"76","author":"Bressanelli","year":"2002","journal-title":"J Virol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/v10010024","article-title":"Visualizing the nucleotide addition cycle of viral RNA-Dependent RNA Polymerase","volume":"10","author":"Wu","year":"2018","journal-title":"Viruses."},{"key":"B25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.chemolab.2016.05.015","article-title":"Computational study on the binding and unbinding mechanism of HCV NS5B with the inhibitor GS-461203 and substrate using conventional and steered molecular dynamics simulations","volume":"156","author":"Pan","year":"2016","journal-title":"Chemom Intell Lab Syst."},{"key":"B26","doi-asserted-by":"publisher","first-page":"7573","DOI":"10.1074\/jbc.RA118.005209","article-title":"The hepatitis C virus RNA-dependent RNA polymerase directs incoming nucleotides to its active site through magnesium-dependent dynamics within its F motif","volume":"294","author":"Ben Ouirane","year":"2019","journal-title":"J Biol Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1126\/science.1259210","article-title":"Structural basis for RNA replication by the hepatitis C virus polymerase","volume":"347","author":"Appleby","year":"2015","journal-title":"Science."},{"key":"B28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.antiviral.2013.11.008","article-title":"Chutes and ladders in hepatitis C nucleoside drug development","volume":"102","author":"Coats","year":"2014","journal-title":"Antiviral Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1003030","DOI":"10.1371\/journal.ppat.1003030","article-title":"Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides","volume":"8","author":"Arnold","year":"2012","journal-title":"PLoS Pathog."},{"key":"B30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.antiviral.2017.04.005","article-title":"Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs","volume":"143","author":"Jin","year":"2017","journal-title":"Antiviral Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.bpj.2014.09.038","article-title":"A critical residue selectively recruits nucleotides for t7 RNA polymerase transcription fidelity control","volume":"107","author":"Duan","year":"2014","journal-title":"Biophys J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J Comput Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1021\/ct300284c","article-title":"Routine access to millisecond time scale events with accelerated molecular dynamics","volume":"8","author":"Pierce","year":"2012","journal-title":"J Chem Theory Comput."},{"key":"B34","article-title":"The PyMOL Molecular Graphics System, Version 1.8","author":"Schr\u00f6dinger","year":"2015"}],"container-title":["Frontiers in Medical Technology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2021.705875\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T08:47:34Z","timestamp":1639471654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2021.705875\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":34,"alternative-id":["10.3389\/fmedt.2021.705875"],"URL":"https:\/\/doi.org\/10.3389\/fmedt.2021.705875","relation":{},"ISSN":["2673-3129"],"issn-type":[{"value":"2673-3129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"article-number":"705875"}}